Table 3.

All causality and treatment-related grade 3–4 adverse events

AE n, %	PF-06263507 mg/kg
	0.1 n = 2		2.78 n = 2		4.34 n = 6		5.42 n = 3		6.5 n = 3
	All	Related	All	Related	All	Related	All	Related	All	Related
Any AEs	1 (50)	0	1 (50)	0	3 (50)	1 (16.7)	1 (33.3)	1 (33.3)	2 (66.7)	1 (33.3)
Thrombocytopenia	0	0	0	0	0	0	0	0	1 (33.3)	1 (33.3)
Eye pain	0	0	0	0	1 (16.7)	1 (16.7)	0	0	0	0
Photophobia	0	0	0	0	1 (16.7)	1 (16.7)	0	0	0	0
Inflammation	0	0	0	0	1 (16.7)	1 (16.7)	0	0	0	0
Hepatobiliary disease	0	0	0	0	0	0	0	0	1 (33.3)	0
Device-related infection	0	0	0	0	1 (16.7)	0	0	0	0	0
Increased AST	0	0	0	0	0	0	1 (33.3)	1 (33.3)	0	0
Increased blood alkaline phosphatase	0	0	0	0	0	0	1 (33.3)	1 (33.3)	0	0
Hypercalcemia	0	0	1 (50)	0	0	0	0	0	0	0
Hyponatremia	1 (50.0)	0	0	0	0	0	0	0	0	0
Hypophosphatemia	0	0	0	0	1 (16.7)	0	0	0	0	0
Embolism	0	0	0	0	1 (16.7)	0	0	0	0	0

AE adverse event, AST aspartate aminotransferase; related, treatment-related